CASYCasey's

Next report: Dec 8; Tuesday, in 26 days · time not announced yet
EPS expected: $6.01; quarter ending Oct 31, 2026
Last result: $4.37Beat; vs $3.44 expected on Jun 8
Stock move on it: −0.10%; two sessions around the report
Price: $706.63; −1.05% today · $32.1B cap

Past and upcoming reports


Dec 8, 2026Upcoming	Oct 31, 2026	Time not announced yet	$6.01	not yet
Jun 8, 2026	Apr 30, 2026	Time not given	$3.44	Beat$4.37	Beat+27.0%	−0.10%2d

Pre-earnings read

No pre-earnings read for this report

None for this company right now.

After the report

Jun 8, 2026 report

Casey's Q4 EPS beats by 31%, shares steady amid overbought conditions

Casey's reported Q4 EPS of $4.37, beating estimates by 31%, with shares nearly flat post-earnings. Despite a strong earnings surprise, valuation remains rich with a forward P/E of 39.6 and RSI indicating overbought conditions. Institutional ownership is high at 88%, and analysts maintain a buy rating with a target near current price levels. Investors should watch upcoming fiscal 2027 execution updates for growth confirmation amid stretched valuation risks.

Reported against expected

Beat

Reported EPS of $4.37 beat estimates of $3.33 by 31.2%.

Guidance

No explicit guidance update provided. analyst consensus remains buy with target price near current levels.

How the stock reacted

Shares rose marginally by 0.07% post-earnings, with recent price momentum strong but RSI at 70.4 signals overbought.

What changed

EPS beat estimates by 31%, confirming strong Q4 profitability and growth momentum.

What the price now assumes

Market shows muted price reaction amid overbought technicals and rich valuation multiples.

What it means for the business

Maintain buy bias but monitor fiscal 2027 execution updates for growth sustainability amid valuation risks.

The next one to three months, as we saw it then

Better case30%

Sustained fiscal 2027 growth and margin expansion validate premium valuation, driving multiple expansion.

Base case50%

Growth continues at moderate pace consistent with analyst forecasts, supporting current valuation.

Worse case20%

Failure to sustain growth amid stretched valuation leads to multiple contraction and share price decline.

If you hold it

Hold unless fiscal 2027 results miss growth forecasts or margins deteriorate materially.

If you are watching

Add only if upcoming quarterly results confirm sustained growth above 10% and margin improvement. avoid if growth falters or valuation multiples expand further without earnings support.

Scenario odds are a judgement, not measured.